While previous studies suggested that Lyn regulates CK2 activity in imatinib-resistant CML cells [83], we did not observe differences in CK2 activity in MYL and MYL-R cells as measured by the phosphorylation of validated CK2 substrates [84], CK2β and EEF1D, (S5D Fig). The gene discussed is CSNK2B; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.